33262228|t|Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET.
33262228|a|OBJECTIVE: To assess whether Alzheimer disease (AD) clinical presentation and APOE4 relate to the burden and topography of beta-amyloid (Abeta) and tau pathologies using in vivo PET imaging. METHODS: We studied 119 Abeta-positive symptomatic patients aged 48-95 years, including 29 patients with logopenic variant primary progressive aphasia (lvPPA) and 21 with posterior cortical atrophy (PCA). Pittsburgh compound B (PiB)-Abeta and flortaucipir (tau)-PET standardized uptake value ratio (SUVR) images were created. General linear models assessed relationships between demographic/clinical variables (phenotype, age), APOE4, and PET (including global cortical and voxelwise SUVR values) while controlling for disease severity using the Clinical Dementia Rating Sum of Boxes. RESULTS: PiB-PET binding showed a widespread cortical distribution with subtle differences across phenotypes and was unrelated to demographic/clinical variables or APOE4. Flortaucipir-PET was commonly elevated in temporoparietal regions, but showed marked phenotype-associated differences, with higher binding observed in occipito-parietal areas for PCA, in left temporal and inferior frontal for lvPPA, and in medial temporal areas for other AD. Cortical flortaucipir-PET binding was higher in younger patients across phenotypes (r = -0.63, 95% confidence interval [CI] -0.72, -0.50), especially in parietal and dorsal prefrontal cortices. The presence of APOE4 was associated with a focal medial temporal flortaucipir-SUVR increase, controlling for all other variables (entorhinal: + 0.310 SUVR, 95% CI 0.091, 0.530). CONCLUSIONS: Clinical phenotypes are associated with differential patterns of tau but not amyloid pathology. Older age and APOE4 are not only risk factors for AD but also seem to affect disease expression by promoting a more medial temporal lobe-predominant pattern of tau pathology.
33262228	15	20	APOE4	Gene	348
33262228	49	66	Alzheimer Disease	Disease	MESH:D000544
33262228	87	90	Tau	Gene	4137
33262228	138	155	Alzheimer disease	Disease	MESH:D000544
33262228	157	159	AD	Disease	MESH:D000544
33262228	187	192	APOE4	Gene	348
33262228	246	251	Abeta	Gene	351
33262228	257	260	tau	Gene	4137
33262228	324	329	Abeta	Gene	351
33262228	351	359	patients	Species	9606
33262228	391	399	patients	Species	9606
33262228	423	450	primary progressive aphasia	Disease	MESH:D018888
33262228	452	457	lvPPA	Disease	MESH:D018888
33262228	471	497	posterior cortical atrophy	Disease	MESH:D001284
33262228	499	502	PCA	Disease	MESH:D001284
33262228	505	526	Pittsburgh compound B	Chemical	MESH:C475519
33262228	528	531	PiB	Chemical	MESH:C475519
33262228	533	538	Abeta	Gene	351
33262228	543	555	flortaucipir	Chemical	MESH:C000591008
33262228	557	560	tau	Gene	4137
33262228	728	733	APOE4	Gene	348
33262228	855	863	Dementia	Disease	MESH:D003704
33262228	894	897	PiB	Chemical	MESH:C475519
33262228	1049	1054	APOE4	Gene	348
33262228	1056	1068	Flortaucipir	Chemical	MESH:C000591008
33262228	1235	1238	PCA	Disease	MESH:D001284
33262228	1282	1287	lvPPA	Disease	MESH:D018888
33262228	1328	1330	AD	Disease	MESH:D000544
33262228	1341	1353	flortaucipir	Chemical	MESH:C000591008
33262228	1388	1396	patients	Species	9606
33262228	1542	1547	APOE4	Gene	348
33262228	1592	1604	flortaucipir	Chemical	MESH:C000591008
33262228	1783	1786	tau	Gene	4137
33262228	1795	1802	amyloid	Disease	MESH:C000718787
33262228	1828	1833	APOE4	Gene	348
33262228	1864	1866	AD	Disease	MESH:D000544
33262228	1974	1977	tau	Gene	4137
33262228	Association	MESH:D001284	351
33262228	Association	MESH:C000591008	348
33262228	Association	MESH:D000544	4137
33262228	Association	MESH:C000591008	MESH:D000544
33262228	Association	MESH:C000591008	MESH:D001284
33262228	Association	MESH:D018888	351
33262228	Association	348	4137
33262228	Association	MESH:C000591008	MESH:D018888
33262228	Association	MESH:D000544	348
33262228	Association	MESH:C475519	351

